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Abstract
Objective
Cognitive impairment (CI) has been described in 3–80% of Systemic lupus erythematosus
(SLE) patients but only short-term studies evaluated its over-time changes, suggesting that
CI is usually a stable finding. We aimed at evaluating the changes of SLE-related CI in a 10-
years prospective single center cohort study.
Methods
We evaluated 43 patients (M/F 5/38; mean age = 45.7±10.1 years; mean disease duration =
230.8±74.3 months) at baseline (T0) and after 10 years (T1). A test battery designed to
detect fronto-subcortical dysfunction across five domains (memory, attention, abstract rea-
soning, executive and visuospatial function) was administered. A global cognitive dysfunc-
tion score (GCD) was obtained and associated with clinical and laboratory features.
Results
Prevalence of CI was 20.9% at T0 and 13.9% at T1 (P = NS). This impairment was preva-
lently mild at T0 (55.5%) and mild or moderate at T1 (36.3% for both degrees). After 10
years, CI improved in 50% of patients, while 10% worsened. Impaired memory (P = 0.02),
executive functions (P = 0.02) and abstract reasoning (P = 0.03) were associated with dysli-
pidemia at T0. Worsening of visuospatial functions was significantly associated with dyslipi-
demia and Lupus Anticoagulant (P = 0.04 for both parameters). Finally, GCD significantly
correlated with chronic damage measured by SLICC/damage index at T0 (r = 0.3; P = 0.04)
and T1 (r = 0.3; P = 0.03).
Conclusions
For the first time, we assessed CI changes over 10-years in SLE. CI improved in the majority
of the patients. Furthermore, we observed an improvement of the overall cognitive functions.
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These results could suggest that an appropriate management of the disease during the fol-
low-up could be able to control SLE-related CI.
Introduction
Systemic Lupus Erythematosus (SLE) is an autoimmune disease characterized by a multifacto-
rial etiology, in which genetic and environmental factors determine disease development [1].
The production of several autoantibodies, often associated with particular phenotypes, charac-
terizes the disease. [2, 3]
Among the different clinical manifestations, neuropsychiatric involvement can affect up to
90% of SLE patients.[4–9] A wide heterogeneity of neurological and psychiatric manifestations
characterizes the neuropsychiatric SLE (NPSLE), as demonstrated by the 19 SLE-associated
neuropsychiatric syndromes included in the standard nomenclature proposed by the Ameri-
can College of Rheumatology (ACR). ] Indeed, NPSLE could widely vary with reference to
severity, ranging from headaches non responsive to narcotics to life-threatening conditions.
Sometimes the diagnosis could be very difficult due to the absence of specific biomarkers or
imaging tools, able to discriminate SLE-related manifestations from other conditions, such as
infections or drug-related adverse events. [10, 11]
Cognitive impairment (CI) represents one of the most common neuropsychiatric feature in
SLE patients, with a prevalence ranging from 3% to 80%. [12–15] This wide range could
depend from several reasons, such as different population assessed, neurocognitive tests
applied to evaluate the manifestation and absence of adequate control groups. Moreover, it
should be considered that some studies evaluated only symptomatic patients while other stud-
ies applied a universal assessment. [5–9, 15]
From a pathogenic point of view, NPSLE development has been related to the presence
of autoantibodies and cytokine-mediated neuronal dysfunctions, vasculopathy, and coa-
gulopathy.[16] Several autoantibodies, potentially exerting a pathogenic role, have been
associated with this involvement: among these anti-phospholipids (aPL), anti-endothelial,
anti-P ribosomal proteins, human N-methyl-D-aspartate (NMDA) receptor types NR2a or
NR2b (anti-NR2) antibodies, anti-neuronal, anti-GAPDH. [17–21] In particular, SLE-CI
seem to be caused by a damage localized in the fronto-subcortical circuits, as demon-
strated by the involvement of domains related to executive functions, attention, learning
and recall, verbal and nonverbal fluency, language, visuospatial skills, and motor dexterity.
[7–9]
With regard to the assessment of SLE-related CI, the ACR Ad Hoc Committee on Neuro-
psychiatric Lupus nomenclature proposed in 1999 a brief research battery able to quantify
these dysfunctions. [4]
So far, the studies assessing cognitive impairment in SLE patients are mostly cross-sec-
tional, without providing information about over-time changes.
To the best of our knowledge, only four longitudinal studies have been conducted, with a
maximum follow-up of 5 years. [22–25] Taken together, these studies suggested that CI is a rel-
atively consistent and stable finding in SLE patients. [22–25] Nonetheless, longer follow-up
may better depict the evolvement of this neuropsychiatric manifestation.
Thus, in the present 10-year prospective study, we aimed at evaluating the changes of CI in
a single center SLE cohort. Secondly, we evaluated the correlations between CI and clinical
and laboratory SLE-related features.
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Patients and methods
Fifty-eight adult patients affected by SLE according to the ACR revised criteria, were enrolled
consecutively in this longitudinal study at the Lupus Clinic, Sapienza University of Rome. [26]
Written informed consent was obtained from each patient and the local ethic committee
approved the study design. The baseline features of this cohort were described in a previous
study. [15]
According to the study protocol, the patients were evaluated at baseline (T0) and after 10
years (T1).
Clinical and laboratory evaluation
Study protocol included complete physical examination and blood drawing. The clinical and
laboratory data were collected in a standardized computerized electronically filled form
including demographics, past medical history with date of diagnosis, co-morbidities, and pre-
vious and concomitant treatments.
Each subject underwent peripheral blood sample collection. The study protocol included
the determination of autoantibodies and the evaluation of C3 and C4 serum levels. Specifically,
ANA has been determined by means of indirect immunofluorescence (IIF) on HEp-2 (titer
 1: 160 or ++ on a scale from + to ++++), anti-dsDNA with IIF on Crithidia Luciliae (titer
 1: 10), ENA (including anti-Ro/SSA, anti-La/SSB, anti-Sm, and anti-RNP) by ELISA assay
considering titers above the cut-off of the reference laboratory, anti-cardiolipin (anti-CL)
(IgG/IgM isotype) by ELISA, in serum or plasma, at medium or high titers (e.g.,>40 GPL or
MPL or above the 99th percentile), anti-β2 Glycoprotein-I (anti-β2GPI) (IgG/IgM isotype) by
ELISA, in serum (above the 99th percentile), and lupus anticoagulant (LA) according to the
guidelines of the International Society on Thrombosis and Hemostasis. Finally, C3 and C4
serum concentrations were determined by means of radial immunodiffusion.
Disease activity and chronic damage
Disease activity was assessed by using the SLE Disease Activity Index 2000 (SLEDAI-2K). [27]
According with the SLEDAI-2K values, we evaluated the number of flares and periods of per-
sistently active disease (PAD) occurring during the follow-up. Flare was defined as an increase
in SLEDAI-2K score 4 from the previous visit with a minimum interval of 2 months between
visits; PAD as a SLEDAI-2K score 4, excluding serology alone, on  2 consecutive visits,
with a minimum interval of 2 months between visits. [28, 29]
The Systemic Lupus International Collaborative Clinics/American College of Rheumatol-
ogy (SLICC/ACR) Damage Index (SDI) was applied to evaluate the chronic damage. [30]
Neurocognitive assessment
All patients underwent a comprehensive cognitive-behavioral neuropsychological assessment,
performed by the same neurologist (CM) at baseline and after 10 years of follow-up.
Neurocognitive assessment was performed during a 1-hour interview and included stan-
dardized testing for five domains: memory, attention, abstract reasoning, executive and visuo-
spatial functions. This assessment included those tests from the ACR and the CSI standardized
in an Italian population, and was specifically designed to detect the fronto-subcortical dysfunc-
tion typical of SLE.
A Minnesota Multiphasic Personality Inventory (MMPI) was administered to all the
patients in order to exclude the influence of behavioral abnormalities on cognitive dysfunc-
tion. [31] The following tests were used:
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• Mini Mental State Examination (MMSE) for general cognitive status [32, 33, 34].
• Rey Auditory Verbal Learning Test and Digit Span forward, two efficient neuropsychologi-
cal instruments for testing verbal memory;
• Immediate Visual Memory Test (an Italian visuospatial test) and Corsi Block-Tapping Test
forward, used to measure visuospatial memory;
• Copying of Drawings with and without elements of programming, two common tools to
evaluate visuospatial abilities;
• Attentive Matrices for both selective and sustained attention;
• Raven’s Progressive Matrices, a widely used non-verbal intelligence test for abstract
reasoning;
• Digit Span backward, Corsi Block-Tapping Test backward, Phonological Verbal Fluency
Test, Trail Making Test A, Trail Making Test B, Wisconsin Card Sorting Test, Analogies
Test and Time andWeight Estimation Test, STEP, to investigate deeply the presence of exec-
utive dysfunctions. [15]
Unadjusted analysis was performed as previously described. [15, 35]
Briefly, for each patient, the raw scores from each test were compared with published
norms (age-, sex-, and education level-corrected, when necessary) and transformed into Z
scores to express the deviation from the normal mean [Z = (raw data2test mean)/test standard
deviation]. Mean domain Z scores (MDZs) were defined as the average of the Z scores from
the tests comprising each domain. To indicate cognitive function as a composite score, the Z
score for each domain was transformed into a Domain Cognitive Dysfunction score (DCDs),
with higher values representing more impairment in a particular domain. The sum of all
DCDs across the five domains resulted in the Global Cognitive Dysfunction score (GCDs),
which was transformed into a Global Cognitive Dysfunction category (GCDc).This method
was summarized in Table 1.
Statistical analysis
The statistical calculations were performed using Statistical Package for Social Sciences 13.0
(SPSS, Chicago, IL, USA) and GraphPad 5.0 (La Jolla, CA, USA). Normally distributed
Table 1. Scoring and categorization of cognitive dysfunction⇤.
Test raw scores Obtained from performance on the neurocognitive testing
Test Z scores Compared with age- and sex-matched published normal values
Mean Domain Z scores (MDZs) Average of the Z scores in the tests comprising each domain
Domain Cognitive Dysfunction Score
(DCDs)
1) if MDZs  -1, then DCDs = 0;
2) if -2MDZs<- 1, then DCDs = 1;
3) if MDZs<-2, then DCDs = 2;
Global Cognitive Dysfunction Score Sum of Domain Cognitive Dysfunction Scores over the 5 domains
(max 10)
Global Cognitive Category Defined from Global Cognitive Dysfunction Score (GCDs)
Absent GCDs 0–1
Mild GCDs 2–3
Moderate GCDs 4–5
Severe GCDs 6
⇤ The composite score is constructed from the bottom to the top of the table.
https://doi.org/10.1371/journal.pone.0196103.t001
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variables were summarized using the mean±SD, and non-normally distributed variables by
the median and interquartile range. Wilcoxon’s matched pairs test and paired t-test were per-
formed. Univariate comparisons between nominal variables were calculated using chi-square
(x2) test or Fisher’s exact test where appropriate. Two-tailed P values were reported, P values
less than or equal to 0.05 were considered significant. GCDs were compared in patients
grouped by antibody level. The binary outcomes variable for the antibody testing were serum
autoantibody status, defined either as present versus absent or low/absent versus high. The
results were verified through analysis of the domain Z scores and single-test Z scores. Descrip-
tive statistics were computed for all study variables. Multivariable logistic regression analysis
was performed including only variables that achieved P value<0.100 in the univariate analysis
were included for calculation.
Results
After a mean follow-up of 119.4±7.2 months, 43 SLE patients (74.1%; M/F 5/38) were re-evalu-
ated: at baseline, these patients showed a mean age of 36.7±10.0 years (range 19–58 years), a
mean disease duration of 110.9±73.6 months, a mean ±SD duration of scholar education of
12.2±3.5 years.
Considering the 15 SLE patients lost to follow-up, 13 refused to participate to the second
evaluation, and two patients died (one for complicated infection and one for cardiovascular
event). No significant differences between re-evaluated and missing patients were observed as
regards demographic, clinical and laboratory features. In Table 2, we reported the main char-
acteristics observed in the 43 SLE patients. These manifestations were cumulative and referred
to the disease history.
With regard to other autoimmune diseases, eleven patients (25.6%) were affected by anti-
phospholipid syndrome (APS), six (13.9%) by Sjo¨gren’s Syndrome. Furthermore, the presence
of comorbidity was registered: arterial hypertension was identified in 21 patients (48.8%), thy-
roid pathology in 15 (34.9%), dyslipidemia, defined as raised plasma triglycerides (  150 mg/
dl) and/or low HDL-C (<40 mg/dl in men and<50 mg/dl in women) [36], in 11 (25.6%), dia-
betes in three (7.0%). During the follow-up, five patients (11.6%) developed peripheral neurop-
athy, 3 (7.0%) a cerebrovascular event, and 2 (4.6%) transverse myelitis. Finally, one patient
(2.3%) developedmyasthenia gravis. In Table 3 the treatments at baseline (T0) and after 10
years (T1) were reported. A significant reduction in mean weekly glucocorticoid (GC) dosage
was identified (P = 0.006).
Data concerning the disease activity and chronic damage are reported in Table 4. A signifi-
cant increase of chronic damage, assessed by using SDI, was observed after 10 years
(P = 0.001).
Cognitive assessment
No alterations in the MMSE were identified in SLE patients at T0 and T1, excluding a severe
impairment of global cognitive status. The assessment by using MMPI depression scale con-
firmed the presence of this mood disorder in 29 patients, previously diagnosed by a neuropsy-
chiatrist specialist. With regard to GCDs, CI was identified in 20.9% (9 patients) at T0 and in
13.9% (6 patients) at T1 (P = NS). This impairment was prevalently mild at T0 (55.5%) and
mild or moderate at T1 (36.3% for both degrees).
Considering patients with CI at baseline, 55.5% experienced an improvement, while the
other patients remained stable. Only one patient among the 34 without CI at baseline experi-
enced a neurocognitive dysfunction with mild impairment.
Cognitive dysfunction modification in SLE patients
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The mean domain Z scores were graphically represented in Fig 1: the domain referring to
executive functions was the most compromised at baseline (0.5±0.8) and after 10-year follow-
up (-0.3±0.7).
All the domains showed an improvement over-time, with a significant difference from
baseline for executive function (P = 0.04). After transforming the MDZs into DCDs, the per-
centage of patients with impairment in the different domains was calculated as shown in Fig 2.
The domain referring to executive functions was the most frequently involved at baseline
(mild/moderate DCDs: 11 patients, 25.6%); this frequency was significantly reduced at the fol-
low-up, when the domain was compromised in six patients (13.9%, P = 0.04). Of note, after 10
years the frequency of impairment was reduced in all the domains evaluated even if without
reaching significant difference.
Moreover, the presence of dyslipidemia, considered in our statistical analysis as a categori-
cal variable, resulted significantly associated with memory impairment (P = 0.02), executive
functions (P = 0.02) and abstract reasoning (P = 0.03) at the baseline, and with visuospatial
functions (P = 0.009) and abstract reasoning (P = 0.004) at T1. Of note, worsening of visuospa-
tial functions was significantly associated with dyslipidemia and positivity for LA (P = 0.04 for
Table 2. Clinical and laboratory features of SLE patients (N = 43) enrolled in the study.
ACR Criteria (N/%) T0 T1 P
Malar Rash 30/69.8 30/69.8 NS
Discoid Lupus 5/11.6 9/20.9 NS
Photosensitivity 17/39.5 19/44.2 NS
Mucosal Ulcers 16/37.2 16/37.2 NS
Arthritis 39/90.7 39/90.7 NS
Serositis 13/30.2 17/39.5 NS
Kidney involvement 16//37.2 17/39.5 NS
Neurologic manifestations 33/76.7 37/86.0 NS
Seizure 6/13.9 6 /13.9
Vascular disease 6/16.3 7/16.3
Mood disorders 29/67.4 29/67.4
Headache 22/51.2 22/51.2
Neuropathy 1/ 2.3 6/13.9
Myelopathy 0 2/4.6
Psychosis 7/16.3 7/16.3
Myasthenia gravis 0 1 /2.3
Movement disorders 1/2.3 1 /2.3
Haematological disorders 36/83.7 36/83.7 NS
Immunologic features 33/76.7 38/88.4 NS
ANA positivity 43/100 43/100 NS
Autoantibodies (N/%)
T0 T1
Anti-dsDNA 25/83.3 30/69.8 NS
Anti-phospholipid 25/83.3 29/67.4 NS
aCL 18/41.8 23/53.5 NS
anti-B2GPI 11/25.6 13/30.2 NS
LA 9/20.9 11/25.6 NS
Legend: ACR: American College of Rheumatology; ANA: antinuclear antibodies; B2GPI: Beta2 Glycoprotein-I; LA:
Lupus Anticoagulant.
https://doi.org/10.1371/journal.pone.0196103.t002
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both parameters). Finally, the GCDs significantly correlated with SDI value at the baseline
(r = 0.3; P = 0.04) and at T1 (r = 0.3; P = 0.03).
No correlations between CI and demographical characteristics (including age and educa-
tion level), SLE clinical features, ongoing and past treatments (specifically GC, immunosup-
pressants and antithrombotic drugs), comorbidities, activity and damage indices were
observed in the present SLE cohort at baseline and follow-up.
Moreover, all the lupus features (such as disease manifestations, antibody levels, disease and
damage scores) and ongoing and past medications (including DMARDS, anticoagulants and
glucocorticoids’ dosage) were considered in the multivariate logistic regression analysis, with-
out identifying significant association.
Moreover no significant associations were identified between CI and behavioral abnormali-
ties evaluated by MMPI scales.
Discussion
In the present longitudinal study, the CI changes after 10 years of follow-up were evaluated in
a cohort of Caucasian SLE patients. We observed an improvement of this manifestation in the
majority of patients evaluated, with a worsening in only 10% of subjects. Furthermore, all cog-
nitive functions improved and a statistically significant difference was achieved for the execu-
tive functions.
Interestingly, the same operator performed the neurocognitive assessment at baseline and
after 10 years, safeguarding the reliability of the results and reducing the risk of performance
Table 3. Treatments at baseline (T0) and after 10 years (T1) of 43 SLE patients.
T0 T1 P
(N = 43) (N = 43)
GC treatment, N/% 31 (72.1) 33 (76.7) NS
Mean dosage±SD (mg/weekly) 60.6± 63.0 31.3± 36.9 0.006
Hydroxychloroquine, N/% 20 (46.5) 21 (48.8) NS
Immunosuppressant drugs (N/%)
Methotrexate 2 (4.6) 1 (2.3) NS
Azathioprine 2 (4.6) 8 (16.6) 0.004
Cyclosporine A 6 (13.9) 3 (7.0) NS
Mycophenolate Mofetil 3 (7.0) 7 (16.3) 0.04
Cyclophosphamide 2 (4.6) - NS
Rituximab - 2 (4.6) NS
Leflunomide 1 (2.3) - NS
Anti-thrombotic treatment (N/%)
Low dose aspirin 12 (27.9) 10 (23.2) NS
Anticoagulation 4 (9.3) 5 (11.6) NS
https://doi.org/10.1371/journal.pone.0196103.t003
Table 4. Disease activity and chronic damage at baseline (T0) and after 10 years (T1) in 43 SLE patients.
Features T0 T1 P
SLEDAI-2K (mean±SD) 2.9±4.4 3.8±3.9 NS
SDI (mean±SD) 1.6±1.8 3.1±2.6 0.001
Number of Flares (mean±SD) - 2.1±2.1 -
PAD: Number (mean±SD) - 1.1±1.1 -
PAD: Duration (mean±SD) - 18.2±13.9 -
https://doi.org/10.1371/journal.pone.0196103.t004
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bias. At the same time, the patients were followed constantly in our Lupus Clinic during the 10
years follow-up, suggesting that clinical decisions among this time lapse were homogenous.
Despite the high number of studies evaluating SLE-related CI, few data have analyzed its
over-time changes, with a maximum follow-up of 5 years. To sum up, in most of the studies a
fluctuating or stable trend was identified more frequently than worsening. [22–25]
The one-year follow-up study of Carlomagno and colleagues demonstrated a stable trend in
more than 90% of SLE-patients. [23]The 5-year evaluation of a 70-patients SLE cohort con-
ducted by Hanly et al. in 1997 identified a reduction of CI prevalence from 21% to 13%. More-
over, the same study suggested that the presence of previous neuropsychiatric events could
predict a CI worsening. [22] According with these results, Gao and colleagues reported a wors-
ening of cognitive ability after 12-month follow-up only in NPSLE patients, in comparison
Fig 1. Distribution of neurocognitive impairment, expressed as MDZ scores ±SD, in the patients enrolled at baseline (T0) and after 10 years.
https://doi.org/10.1371/journal.pone.0196103.g001
Fig 2. Percentage of patients with neurocognitive impairment, expressed as DCDs, in all the domains evaluated at T0 and T1. Absent: DCD = 0; Mild: DCD = 1;
Moderate: DCD = 2.
https://doi.org/10.1371/journal.pone.0196103.g002
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with non-NPSLE and healthy control. [25] Waterloo and colleagues investigated the changes
of different neuro-psychological variables after 5years of follow-up in a 28-patients cohort. In
particular, a stable pattern was identified in all variables but two (namely, Category test and
Seashore Rhythm Test). [24]
We previously evaluated a 58-patients SLE cohort in order to assess the CI prevalence and
the possible association with other clinical and laboratory SLE-related features. We observed a
mild GCDs impairment in 19% of patients, moderate (GCDs 4–5) in 7% and severe in 5%.(15)
In this cohort, the impairment of visuospatial domain resulted the most compromised and sig-
nificantly associated with aCL IgM levels. Moreover, disease activity and chronic damage cor-
related with different domains. [15]
In the present study, we re-evaluated 43 out of 58 patients (74.1%), observing a reduction of
the CI prevalence from 20.9to 13.9% after 10-yearfollow-up. Specifically, half of patients with
CI at the baseline showed an improvement and only 10% a worsening. These results reinforce
those obtained in above-described studies: in our cohort, even the majority of patients experi-
enced an improvement of cognitive functions, differently from the stable trend previously
described. We could hypothesize that the improved management of SLE patients and new
therapeutic strategies allowed these results. In fact, previous studies were conducted more than
10 years ago and a wider knowledge on the SLE management as well as of therapeutic arrows
can be expected in this time interval. [37, 38]
This suggestion was confirmed indirectly by the comparison of treatments at baseline and
after 10 years. Of note, a significantly lower mean weekly dosage of GC was documented at the
follow-up, with a significant increase of percentage of patients assuming dosage lower than
35mg/weekly of prednisone equivalents. Moreover, in our cohort we observed a significant
increase of immunosuppressant drugs administration (in particular, Azathioprine and Myco-
phenolate) and the appearance of biological drugs usage. Of note, in the last years a growing
use of Mycophenolate was registered in Lupus cohorts, demonstrating the efficacy of this drug
in other than renal involvement features, such as neurological manifestations. [39]
Furthermore, all patients were treated by antimalarial drugs and/or immunosuppressant
and, in case of positivity for aPL antibodies, by anti-thrombotic therapy. Taken together, these
treatments could influence the different inflammatory and thrombotic pathogenic mecha-
nisms potentially determining CI. Nonetheless, it should be considered that the low mean age
at the baseline (lower than 40 years) and the high scholar level of our cohort could influence
the ability to perform neurocognitive assessment.
Furthermore, we evaluated the association between CI and the different clinical/laboratory
SLE-related features, as well as cardiovascular comorbidities. We observed a significant associ-
ation between dyslipidemia and CI in all the domains, except for the attention, at baseline and
after 10 years. Moreover, this comorbidity significantly correlated with the worsening of visuo-
spatial functions. These results are in agreement with previous evidences: in particular, a mul-
ticenter Italian study including about 1.000 SLE patients identified dyslipidemia as a risk
factor for the presence of CI. [40]
We could hypothesize, as a possible pathogenetic explanation, a concurrent subclinical vas-
cular injury in both dyslipidemic and cognitive impaired patients which may justify this
association.
In addition, our analysis confirms the possible pathogenic role of aPL in the CI development:
a significant correlation between LA positivity and the worsening in visuospatial functions was
identified in our cohort. This finding suggests that aPL may act determining not only a focal
damage (at level of thrombotic event), but also a more diffuse damage, with a direct mechanism
on neural cells. [41, 42] Moreover, disease activity and chronic damage seem to influence CI.
Interestingly, the presence of flares assessed according with SLEDAI-2K modifications, resulted
Cognitive dysfunction modification in SLE patients
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significantly associated with a worsening in the memory domain. This result suggests that the
prevention of disease relapse could control the involvement of cognitive functions.
We would highlight that generally MMPI is not an optimal battery to evaluate mood disor-
ders. However, since at baseline evaluation, performed about 10 years ago, MMPI has been
chosen to exclude the influence of behavioral abnormalities on cognitive dysfunction, we
decided to keep the same protocol in order to maintain continuity and consistency of our lon-
gitudinal study. Nonetheless we observed that the assessment by MMPI depression scale
indeed confirmed the presence of this mood disorder in the same patients previously diag-
nosed by a neuropsychiatrist specialist. Thus, all MMPI scales were included in the multivari-
ate analysis but did not correlate with CI identified.
In conclusion, the present study provides data concerning the changes over-time of SLE-
related CI, by considering for the first time a follow-up of 10 years. Our data demonstrated a
stability of cognitive functions, with a trend to the improvement in all the evaluated domains.
The risk factors for a worse prognosis resulted the positivity for aPL, in particular LA, and the
presence of a concomitant dyslipidemia. Moreover, the prevention of disease relapse and
chronic damage development is mandatory in order to prevent CI worsening.
Author Contributions
Conceptualization: Fulvia Ceccarelli, Guido Valesini, Fabrizio Conti.
Data curation: Fulvia Ceccarelli, Carlo Perricone, Carmelo Pirone, Laura Massaro, Cristiano
Alessandri, Concetta Mina, Massimo Marianetti, Francesca Romana Spinelli, Fabrizio
Conti.
Formal analysis: Fulvia Ceccarelli, Carlo Perricone, Carmelo Pirone, Concetta Mina, Fabrizio
Conti.
Investigation: Laura Massaro, Cristiano Alessandri, Massimo Marianetti, Francesca Romana
Spinelli.
Methodology: Fulvia Ceccarelli, Carlo Perricone, Guido Valesini, Fabrizio Conti.
Software: Carmelo Pirone.
Supervision: Fulvia Ceccarelli.
Visualization: Fulvia Ceccarelli, Carlo Perricone, Carmelo Pirone, Laura Massaro, Cristiano
Alessandri, Concetta Mina, Massimo Marianetti, Francesca Romana Spinelli, Guido Vale-
sini, Fabrizio Conti.
Writing – original draft: Fulvia Ceccarelli, Carlo Perricone, Carmelo Pirone, Concetta Mina,
Guido Valesini, Fabrizio Conti.
Writing – review & editing: Fulvia Ceccarelli, Fabrizio Conti.
References
1. Tsokos GC. Systemic lupus erythematosus. The New England journal of medicine. 2011; 365
(22):2110–21. https://doi.org/10.1056/NEJMra1100359 PMID: 22129255
2. Conti F, Ceccarelli F, Perricone C, Massaro L, Marocchi E, Miranda F, et al. Systemic Lupus Erythema-
tosus with and without Anti-dsDNA Antibodies: Analysis from a Large Monocentric Cohort. Mediators of
inflammation. 2015; 2015:328078. https://doi.org/10.1155/2015/328078 PMID: 26063969
3. Yaniv G, Twig G, Shor DB, Furer A, Sherer Y, Mozes O, et al. A volcanic explosion of autoantibodies in
systemic lupus erythematosus: a diversity of 180 different antibodies found in SLE patients. Autoimmu-
nity reviews. 2015; 14(1):75–9. https://doi.org/10.1016/j.autrev.2014.10.003 PMID: 25449682
Cognitive dysfunction modification in SLE patients
PLOS ONE | https://doi.org/10.1371/journal.pone.0196103 May 3, 2018 10 / 12
4. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus
syndromes. Arthritis and rheumatism. 1999; 42(4):599–608. https://doi.org/10.1002/1529-0131
(199904)42:4<599::AID-ANR2>3.0.CO;2-F PMID: 10211873
5. Buchbinder R, Hall S, Littlejohn GO, Ryan PF. Neuropsychiatric manifestations of systemic lupus ery-
thematosus. Australian and New Zealand journal of medicine. 1988; 18(5):679–84. PMID: 3245822
6. Utset TO, Golden M, Siberry G, Kiri N, Crum RM, Petri M. Depressive symptoms in patients with sys-
temic lupus erythematosus: association with central nervous system lupus and Sjogren’s syndrome.
The Journal of rheumatology. 1994; 21(11):2039–45. PMID: 7869307
7. Carbotte RM, Denburg SD, Denburg JA. Prevalence of cognitive impairment in systemic lupus erythe-
matosus. The Journal of nervous and mental disease. 1986; 174(6):357–64. PMID: 3711879
8. Hay EM, Black D, Huddy A, Creed F, Tomenson B, Bernstein RM, et al. Psychiatric disorder and cogni-
tive impairment in systemic lupus erythematosus. Arthritis and rheumatism. 1992; 35(4):411–6. PMID:
1567490
9. Kozora E, Thompson LL, West SG, Kotzin BL. Analysis of cognitive and psychological deficits in sys-
temic lupus erythematosus patients without overt central nervous system disease. Arthritis and rheuma-
tism. 1996; 39(12):2035–45. PMID: 8961909
10. Govoni M, Bortoluzzi A, Padovan M, Silvagni E, Borrelli M, Donelli F, et al. The diagnosis and clinical
management of the neuropsychiatric manifestations of lupus. Journal of autoimmunity. 2016; 74:41–72.
https://doi.org/10.1016/j.jaut.2016.06.013 PMID: 27427403
11. Unterman A, Nolte JE, Boaz M, Abady M, Shoenfeld Y, Zandman-Goddard G. Neuropsychiatric syn-
dromes in systemic lupus erythematosus: a meta-analysis. Seminars in arthritis and rheumatism. 2011;
41(1):1–11. https://doi.org/10.1016/j.semarthrit.2010.08.001 PMID: 20965549
12. Sanna G, Bertolaccini ML, Cuadrado MJ, Laing H, Khamashta MA, Mathieu A, et al. Neuropsychiatric
manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid anti-
bodies. The Journal of rheumatology. 2003; 30(5):985–92. PMID: 12734893
13. Afeltra A, Garzia P, Mitterhofer AP, Vadacca M, Galluzzo S, Del Porto F, et al. Neuropsychiatric lupus
syndromes: relationship with antiphospholipid antibodies. Neurology. 2003; 61(1):108–10. PMID:
12847168
14. Zhou HQ, Zhang FC, Tian XP, Leng XM, Lu JJ, Zhao Y, et al. Clinical features and outcome of neuro-
psychiatric lupus in Chinese: analysis of 240 hospitalized patients. Lupus. 2008; 17(2):93–9. https://doi.
org/10.1177/0961203307085671 PMID: 18250131
15. Conti F, Alessandri C, Perricone C, Scrivo R, Rezai S, Ceccarelli F, et al. Neurocognitive dysfunction in
systemic lupus erythematosus: association with antiphospholipid antibodies, disease activity and
chronic damage. PloS one. 2012; 7(3):e33824. https://doi.org/10.1371/journal.pone.0033824 PMID:
22461897
16. Ho RC, Thiaghu C, Ong H, Lu Y, Ho CS, Tam WW, et al. A meta-analysis of serum and cerebrospinal
fluid autoantibodies in neuropsychiatric systemic lupus erythematosus. Autoimmunity reviews. 2016; 15
(2):124–38. https://doi.org/10.1016/j.autrev.2015.10.003 PMID: 26497108
17. Perricone C, Pendolino M, Olivieri M, Conti F, Valesini G, Alessandri C. Neuropsychiatric manifesta-
tions associated with anti-endothelial cell antibodies in systemic lupus erythematosus. The Israel Medi-
cal Association journal: IMAJ. 2015; 17(3):171–8. PMID: 25946769
18. Delunardo F, Soldati D, Bellisario V, Berry A, Camerini S, Crescenzi M, et al. Anti-GAPDH Autoantibod-
ies as a Pathogenic Determinant and Potential Biomarker of Neuropsychiatric Diseases. Arthritis &
rheumatology (Hoboken, NJ). 2016; 68(11):2708–16.
19. Shi ZR, Cao CX, Tan GZ, Wang L. The association of serum anti-ribosomal P antibody with clinical and
serological disorders in systemic lupus erythematosus: a systematic review and meta-analysis. Lupus.
2015; 24(6):588–96. https://doi.org/10.1177/0961203314560003 PMID: 25406488
20. Tay SH, Fairhurst AM, Mak A. Clinical utility of circulating anti-N-methyl-d-aspartate receptor subunits
NR2A/B antibody for the diagnosis of neuropsychiatric syndromes in systemic lupus erythematosus
and Sjogren’s syndrome: An updated meta-analysis. Autoimmunity reviews. 2017; 16(2):114–22.
https://doi.org/10.1016/j.autrev.2016.12.002 PMID: 27988431
21. Valesini G, Alessandri C, Celestino D, Conti F. Anti-endothelial antibodies and neuropsychiatric sys-
temic lupus erythematosus. Annals of the New York Academy of Sciences. 2006; 1069:118–28. https://
doi.org/10.1196/annals.1351.010 PMID: 16855139
22. Hanly JG, Cassell K, Fisk JD. Cognitive function in systemic lupus erythematosus: results of a 5-year
prospective study. Arthritis and rheumatism. 1997; 40(8):1542–3. https://doi.org/10.1002/1529-0131
(199708)40:8&lt;1542::AID-ART26&gt;3.0.CO;2-9 PMID: 9259438
Cognitive dysfunction modification in SLE patients
PLOS ONE | https://doi.org/10.1371/journal.pone.0196103 May 3, 2018 11 / 12
23. Carlomagno S, Migliaresi S, Ambrosone L, Sannino M, Sanges G, Di Iorio G. Cognitive impairment in
systemic lupus erythematosus: a follow-up study. Journal of neurology. 2000; 247(4):273–9. PMID:
10836619
24. Waterloo K, Omdal R, Husby G, Mellgren SI. Neuropsychological function in systemic lupus erythema-
tosus: a five-year longitudinal study. Rheumatology (Oxford, England). 2002; 41(4):411–5.
25. Gao Y, Lau EY, Wan JH, Lau CS, Mok MY. Systemic lupus erythematosus patients with past neuropsy-
chiatric involvement are associated with worse cognitive impairment: a longitudinal study. Lupus. 2016;
25(6):637–44. https://doi.org/10.1177/0961203315624022 PMID: 26700182
26. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of
systemic lupus erythematosus. Arthritis and rheumatism. 1997; 40(9):1725.
27. Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. The
Journal of rheumatology. 2002; 29(2):288–91. PMID: 11838846
28. Nikpour M, Urowitz MB, Ibanez D, Gladman DD. Frequency and determinants of flare and persistently
active disease in systemic lupus erythematosus. Arthritis and rheumatism. 2009; 61(9):1152–8. https://
doi.org/10.1002/art.24741 PMID: 19714602
29. Conti F, Ceccarelli F, Perricone C, Miranda F, Truglia S, Massaro L, et al. Flare, persistently active dis-
ease, and serologically active clinically quiescent disease in systemic lupus erythematosus: a 2-year fol-
low-up study. PloS one. 2012; 7(9):e45934. https://doi.org/10.1371/journal.pone.0045934 PMID:
23029327
30. Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, et al. The development and initial val-
idation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology
damage index for systemic lupus erythematosus. Arthritis and rheumatism. 1996; 39(3):363–9. PMID:
8607884
31. Hahn RC, Petitti DB. Minnesota Multiphasic Personality Inventory-rated depression and the incidence
of breast cancer. Cancer. 1988; 61(4):845–8. PMID: 3338043
32. Folstein MF, Folstein SE, McHugh PR. ‘‘Mini-mental state”. A practical method for grading the cognitive
state of patients for the clinician. J Psychiatr Res 1975; 12:189–9. PMID: 1202204
33. Lukhanina EP, Kapustina MT, Berezetskaya NM, Karaban IN. Reduction of the postexcitatory cortical
inhibition upon paired-click auditory stimulation in patients with Parkinson’s disease. Clin Neurophysiol.
2009; 120:1852–8 https://doi.org/10.1016/j.clinph.2009.07.040 PMID: 19767236
34. Shimada H, Makizako H, Doi T, Park H, Tsutsumimoto K, Verghese J, Suzuki T. Effects of Combined
Physical and Cognitive Exercises on Cognition and Mobility in Patients With Mild Cognitive Impairment:
A Randomized Clinical Trial. J Am Med Dir Assoc. 2017 Nov 16
35. Lapteva L, Nowak M, Yarboro CH, Takada K, Roebuck-Spencer T, Weickert T, et al. Anti-N-methyl-D-
aspartate receptor antibodies, cognitive dysfunction, and depression in systemic lupus erythematosus.
Arthritis and rheumatism. 2006; 54(8):2505–14. https://doi.org/10.1002/art.22031 PMID: 16868971
36. Lam DW, LeRoith D. Metabolic Syndrome. In: De Groot LJ, Chrousos G, Dungan K, Feingold KR,
Grossman A, Hershman JM, Koch C, Korbonits M, McLachlan R, New M, Purnell J, Rebar R, Singer F,
Vinik A, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2015.
37. van Vollenhoven RF, Mosca M, Bertsias G, Isenberg D, Kuhn A, Lerstrom K, et al. Treat-to-target in
systemic lupus erythematosus: recommendations from an international task force. Annals of the rheu-
matic diseases. 2014; 73(6):958–67. https://doi.org/10.1136/annrheumdis-2013-205139 PMID:
24739325
38. Mok CC. Biological and targeted therapies of systemic lupus erythematosus: evidence and the state of
the art. Expert review of clinical immunology. 2017.
39. Conti F, Ceccarelli F, Perricone C, Massaro L, Cipriano E, Pacucci VA, et al. Mycophenolate mofetil in
systemic lupus erythematosus: results from a retrospective study in a large monocentric cohort and
review of the literature. Immunologic research. 2014; 60(2–3):270–6. https://doi.org/10.1007/s12026-
014-8609-x PMID: 25468307
40. Govoni M, Bombardieri S, Bortoluzzi A, Caniatti L, Casu C, Conti F, et al. Factors and comorbidities
associated with first neuropsychiatric event in systemic lupus erythematosus: does a risk profile exist?
A large multicentre retrospective cross-sectional study on 959 Italian patients. Rheumatology (Oxford,
England). 2012; 51(1):157–68.
41. Cimaz R, Meroni PL, Shoenfeld Y. Epilepsy as part of systemic lupus erythematosus and systemic anti-
phospholipid syndrome (Hughes syndrome). Lupus. 2006; 15(4):191–7. https://doi.org/10.1191/
0961203306lu2272rr PMID: 16686257
42. Appenzeller S, Lapa AT, de Carvalho JF, Peres FA, Shoenfeld Y. Cognitive dysfunction and antipho-
spholipid antibodies. Current rheumatology reports. 2012; 14(1):95–8. https://doi.org/10.1007/s11926-
011-0224-4 PMID: 22134844
Cognitive dysfunction modification in SLE patients
PLOS ONE | https://doi.org/10.1371/journal.pone.0196103 May 3, 2018 12 / 12
